Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leukemia, Myelomonocytic, Juvenile

ClinicalTrials.gov lists 124 trials for Leukemia, Myelomonocytic, Juvenile or a narrower condition beneath it. Children's Oncology Group has the most among industry and government lead sponsors, with 11.

MeSH D054429 Neoplasms Neoplasm C04 C15 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 23 Phase 1/2 Phase 1/2 11 Phase 2 Phase 2 45 Phase 3 Phase 3 12 Phase 4 Phase 4 1 Not applicable Not applicable 14 Observational Observational 18 Phase 1 Phase 1 23 Phase 1/2 Phase 1/2 11 Phase 2 Phase 2 45 Phase 3 Phase 3 12 Phase 4 Phase 4 1 Not applicable Not applicable 14 Observational Observational 18

Trials per phase (log scale)

124 of the 124 trials are tagged with Leukemia, Myelomonocytic, Juvenile itself; the rest are tagged with a narrower condition beneath it.

Get the Leukemia, Myelomonocytic, Juvenile report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leukemia, Myelomonocytic, Juvenile trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 12

1991: 1 trials (Observational 1) 1995: 1 trials (Phase 2 1) 1996: 2 trials (Observational 2) 1998: 3 trials (Phase 3 1, Phase 2 1, Phase 1 1) 1999: 6 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 1/2 2) 2000: 5 trials (Not applicable 1, Phase 2 3, Phase 1/2 1) 2001: 3 trials (Phase 2 2, Phase 1 1) 2002: 5 trials (Phase 3 4, Phase 1 1) 2003: 10 trials (Observational 1, Not applicable 3, Phase 2 3, Phase 1/2 3) 2004: 9 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2 3, Phase 1 1) 2005: 10 trials (Observational 1, Not applicable 1, Phase 2 4, Phase 1 4) 2006: 8 trials (Not applicable 1, Phase 2 5, Phase 1/2 2) 2007: 12 trials (Observational 1, Phase 3 1, Phase 2 4, Phase 1 6) 2008: 7 trials (Observational 3, Phase 3 2, Phase 2 1, Phase 1 1) 2009: 4 trials (Observational 2, Not applicable 1, Phase 2 1) 2010: 4 trials (Observational 1, Not applicable 1, Phase 2 1, Phase 1 1) 2011: 5 trials (Phase 4 1, Phase 3 1, Phase 2 2, Phase 1 1) 2012: 2 trials (Phase 2 2) 2013: 2 trials (Phase 2 1, Phase 1/2 1) 2014: 1 trials (Phase 2 1) 2015: 5 trials (Observational 2, Phase 2 3) 2016: 2 trials (Phase 2 1, Phase 1 1) 2017: 1 trials (Phase 1 1) 2018: 3 trials (Phase 2 2, Phase 1 1) 2019: 4 trials (Not applicable 1, Phase 2 1, Phase 1 2) 2022: 2 trials (Phase 3 1, Phase 1/2 1) 2023: 2 trials (Phase 2 2) 2024: 2 trials (Phase 2 1, Phase 1/2 1) 2025: 1 trials (Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2025 1
2024 2
2023 2
2022 2
2019 4
2018 3
2017 1
2016 2
2015 5

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 55 months across 93 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leukemia, Myelomonocytic, Juvenile trials in? (7)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 23
Phase 1/2 11
Phase 2 45
Phase 3 12
Phase 4 1
Not applicable 14
Observational 18

How many Leukemia, Myelomonocytic, Juvenile trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Recruiting 11
Active, not recruiting 7
Completed 73
Terminated 19

Showing 5 of 7 statuses.

Start your 14-day trial Email me all 7 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leukemia, Myelomonocytic, Juvenile trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Children's Oncology Group 11
National Cancer Institute (NCI) 5
Celgene 2

Which drugs are being tested for Leukemia, Myelomonocytic, Juvenile? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 31
Busulfan 20
Melphalan 17
METHYLPREDNISOLONE 11

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 33
Mofetil Mycophenolate 24
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] 23
IR Tacrolimus 19
Peripheral blood stem cell transplantation 18

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leukemia, Myelomonocytic, Juvenile trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Death 213 5
Graft versus host disease (GVHD) 47 2
Febrile neutropenia 27 6
Hypoxia 26 11
Infection 22 6

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Leukemia, Myelomonocytic, Juvenile? (10)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group. Cancer discovery 2024 Yes
Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay. JCO precision oncology 2023 Yes
Treatment advances for pediatric and adult onset neoplasms with monocytosis. Current hematologic malignancy reports 2021 Yes
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood advances 2021 Yes
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. Seminars in cancer biology 2018 Yes

Showing 5 of 10 publications.

Start your 14-day trial Email me all 10 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Juvenile myelomonocytic leukemia Point prevalence 1-9 / 1 000 000 Europe Not stated Exact
Juvenile myelomonocytic leukemia Point prevalence 1-9 / 1 000 000 Europe Not stated Unspecified
Juvenile myelomonocytic leukemia Point prevalence 1-9 / 1 000 000 Europe Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Juvenile myelomonocytic leukemia 86834 Exact Orphadata Science knowledge files, Product 1
Juvenile myelomonocytic leukemia 86834 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages